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Summary
Familial, sequencing, and genome-wide association studies (GWASs) and genetic correlation 
analyses have progressively unraveled the shared or pleiotropic germline genetics of breast and 
ovarian cancer. In this study, we aimed to leverage this shared germline genetics to improve the 
power of transcriptome-wide association studies (TWASs) to identify candidate breast cancer and 
ovarian cancer susceptibility genes. We built gene expression prediction models using the 
PrediXcan method in 681 breast and 295 ovarian tumors from The Cancer Genome Atlas and 211 
breast and 99 ovarian normal tissue samples from the Genotype-Tissue Expression project and 
integrated these with GWAS meta-analysis data from the Breast Cancer Association Consortium 
(122,977 cases/105,974 controls) and the Ovarian Cancer Association Consortium (22,406 cases/
40,941 controls). The integration was achieved through application of a pleiotropy-guided 
conditional/conjunction false discovery rate (FDR) approach in the setting of a TWASs. This 
identified 14 candidate breast cancer susceptibility genes spanning 11 genomic regions and 8 
candidate ovarian cancer susceptibility genes spanning 5 genomic regions at conjunction FDR < 
0.05 that were >1 Mb away from known breast and/or ovarian cancer susceptibility loci. We also 
identified 38 candidate breast cancer susceptibility genes and 17 candidate ovarian cancer 
susceptibility genes at conjunction FDR < 0.05 at known breast and/or ovarian susceptibility loci. 
The 22 genes identified by our cross-cancer analysis represent promising candidates that further 
elucidate the role of the transcriptome in mediating germline breast and ovarian cancer risk.
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The last three decades have witnessed major advances in our understanding of the shared 
inherited genetic basis of breast and ovarian cancer. The identification of rare inherited 
mutations in BRCA1 (MIM: 113705)1 and BRCA2 (MIM: 600185)2 that confer high risks 
of developing both breast and ovarian cancer has directly opened up the identification of 
oncogenic mechanisms leading to the development of poly ADP ribose polymerase inhibitor 
therapy.3 The findings from genome-wide association studies (GWASs) have demonstrated 
that there is a strong genetic correlation between breast and ovarian cancer4 and have 
identified several genomic regions containing common (minor allele frequency > 1%) 
variants that confer risk of developing both breast and ovarian cancer.5,6
Transcriptome-wide association studies (TWASs) represent the latest study design for the 
identification of disease-associated susceptibility genes. TWASs involve establishing robust 
multi-variant models for the component of somatic (normal or tumor) gene expression that is 
regulated by germline genetic variation in a smaller dataset where both germline genotype 
and somatic transcriptomic data are available. These models are then used to impute the 
germline genetically regulated component of gene expression into a larger GWAS dataset 
where measured gene expression is unavailable but that offers significantly improved power 
to identify genes associated with disease risk where such risk may be mediated by 
expression. Moving from single variants (GWASs) to genes (TWASs) as the unit of 
association reduces the multiple testing burden. The use of gene expression provides a 
readily accessible readout of the functional basis of the identified association in contrast to 
GWAS-identified risk variants that predominantly reside in non-coding regions of the 
genome.7
PrediXcan is a method developed recently for conducting TWASs.8 TWAS methods have 
been applied to single cancer types before, including breast cancer9,10 and ovarian cancer.
11,12 Here we present an application of PrediXcan, and indeed broadly of TWASs, in the 
pleiotropic cross-cancer setting. We used the normal and tumor breast- and ovary-specific 
gene expression and matched germline genotype datasets to generate tissue-specific 
PrediXcan models and first imputed these models into GWAS data for the corresponding 
cancers (i.e., from breast-tissue-derived models into breast cancer GWASs and likewise for 
the ovarian models). We then imputed models across cancer types (i.e., from breast-tissue-
derived models into ovarian cancer GWASs and vice versa). Finally, we implemented a 
powerful conjunction false discovery rate (FDR) approach13,14 that has been applied 
previously to GWASs,15-18 but not to TWASs, to leverage the combined GWAS sample of 
over 145,000 breast and ovarian cancer cases. We identify candidate breast and ovarian 
cancer susceptibility genes in regions not previously implicated by GWAS or TWAS 
analyses of these cancers.
Material and methods
Matched germline genotype: normal/tumor gene expression datasets
We used data for 211 normal breast tissue samples and 99 normal ovarian tissue samples 
from the Genotype-Tissue Expression (GTEx) project (version 7 release).19 Germline 
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genotypes in the GTEx data had been called from whole-genome sequencing (Illumina 
HiSeq X), and gene expression was profiled using RNA-sequencing (Illumina TruSeq). We 
also used data from 681 breast cancer20 and 295 high-grade serous ovarian cancer 
(HGSOC)21 cases from The Cancer Genome Atlas (TCGA) network. Germline genotypes in 
the TCGA data had been called from genotyping arrays (Affymetrix SNP 6.0), and gene 
expression was profiled using RNA-sequencing (Illumina HiSeq 2000). Imputation of 
TCGA germline genotypes using the 1000 Genomes version 5 reference panel was 
performed as described previously.22,23 TCGA sample sizes reported here refer to only those 
samples that had >95% European ancestry. Ancestry was estimated using the Local Ancestry 
in adMixed Populations tool (LAMP version 2.5).24 Downstream PrediXcan modeling 
(described below) used variants imputed with quality > 0.8 that had a minor allele frequency 
> 5% in TCGA datasets.
Genome-wide association datasets
Summary statistics from genome-wide association meta-analyses were obtained from the 
Breast Cancer Association Consortium (BCAC)22 and the Ovarian Cancer Association 
Consortium (OCAC).23 The breast cancer susceptibility data were based on 122,977 cases 
and 105,974 controls, including 21,468 estrogen receptor (ER)-negative cases. The ovarian 
cancer susceptibility data were based on 22,406 epithelial ovarian cancer cases and 40,941 
controls, including 13,037 HGSOC cases. We harmonized the signs of the effect size 
estimates and aligned them to the same effect allele in the breast and ovarian cancer GWAS 
datasets. We retained 9,530,997 variants with minor allele frequency > 1% and imputation 
quality > 0.4 in both datasets for S-PrediXcan analyses. All individuals in these studies were 
of genetically inferred European ancestry.
PrediXcan model development and S-PrediXcan analyses
We built genetically regulated gene expression prediction models using the elastic net 
regularization approach implemented in PrediXcan and validated these models using tenfold 
cross-validation.8 Essentially, this generates a list of variants for each gene where model 
construction is successful and each variant in the list is assigned a weight reflecting its 
influence on its target gene expression. Genes with models where the nested tenfold cross-
validated correlation between predicted and actual levels of expression was >10% 
(predictive performance r2 > 0.01) and p value of the correlation test was <0.05 were 
retained. These models were adjusted for the latent determinants of gene expression 
variation (referred to hereafter as PEER factors), which were identified using the 
Probabilistic Estimation of Expression Residuals (PEER; version 1.3) method.25 We 
adjusted for 60 and 45 PEER factors for TCGA breast and ovarian cancer data, respectively. 
The choice of these numbers is a function of sample size and consistent with 
recommendations.8,25 ESR1 expression was also included as a covariate in the construction 
of breast cancer models to account for ER status and its influence on the expression of 
individual genes. For the GTEx version 7 datasets, we downloaded pre-computed PrediXcan 
models from predictdb.org. Our pipeline for processing the TCGA datasets, including the 
application of PEER factors, was designed to be consistent with the pipeline used to 
generate the pre-computed GTEx PrediXcan models. S-PrediXcan refers to the application 
of the PrediXcan gene expression models, specifically the variant weights from elastic net 
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combined into multi-variant gene-level instruments, to summary statistics GWAS datasets 
and has been described in detail before.8 The variance of a gene’s expression that was 
explained by the SNPs in its model was calculated as W′ × G × W (where W is the vector of 
SNP weights in a gene’s model, W′ is its transpose, and G is the covariance matrix).
Conditional and conjunction FDR analyses
We obtained p values for association of predicted expression of each gene with breast cancer 
risk and with ovarian cancer risk. We then computed the FDR for gene-breast cancer risk 
association conditional on gene-ovarian cancer risk association (as conditional 
FDRBreast Cancer∣Ovarian Cancer). This is the probability that a gene is not associated with 
breast cancer risk given the p values for association with both breast cancer risk and ovarian 
cancer risk. The analogous conditional FDR for gene-ovarian cancer risk association was 
also calculated (FDROvarian Cancer∣Breast Cancer). Finally, the conjunctional FDR estimate, 
which is conservatively defined as the maximum of the two conditional FDR values, was 
computed. This process minimizes the effect of a single phenotype (in this case, breast or 
ovarian cancer) driving the shared association signal. It allows the power of pleiotropic 
associations to be tapped for genetic discovery, unlike a traditional FDR approach that is 
informed solely by the distribution of p values for a single phenotype. We used the R 
implementation of the conditional FDR method. The conditional and conjunctional FDR 
method has been described extensively elsewhere13-18 but not applied before to the TWAS 
setting. The overall study design is summarized in Figure 1.
Fine-mapped candidate causal risk variant datasets
We examined the overlap between variants in the breast gene expression prediction models 
and a published list of fine-mapped candidate causal risk variants for breast cancer.26 This 
was done to follow up genes that we identified in genomic regions that are known to be 
associated with breast cancer risk under the intuition that gene-level association signals 
identified by S-PrediXcan that demonstrate such overlap with fine-mapped variants are 
likely being driven by the GWAS association signal in the same region.
Fine-mapped candidate causal risk variants lists for breast cancer were obtained from Fachal 
et al.26 Briefly, Fachal et al. fine-mapped 150 known breast cancer susceptibility regions 
using dense genotype data on women participating in the BCAC and in the Consortium of 
Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise multinomial logistic regression 
was used to identify independent association signals in each region. Credible causal variants 
within each signal were defined as being within a 100-fold likelihood of the top conditional 
variant to delineate the variants driving the GWAS associations in each region.
We adopted a similar analytic strategy for the ovarian cancer dataset from OCAC. Each 
genomic region with a genome-wide significant (p < 5 × 10−8) variant was explored to 
identify additional independent association signals. All variants within a given genomic 
region were jointly analyzed to evaluate the simultaneous effects of multiple variants, using 
a 1 Mb window centered on the most significant variant, in stepwise conditional models. 
Given the presence of a genome-wide significant variant in the region, the prior probability 
of an additional risk variant in the same region is higher than in a region without a genome-
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wide significant lead variant; therefore, we used a threshold of p < 1 × 10−5 to identify 
additional independent association signals. All variants in each region were ranked by the 
likelihood of association with ovarian cancer based on p values. The likelihood of each 
variant was then compared with the likelihood of the lead variant in the region based on the 
primary association analysis for primary signals and the conditional association analysis for 
conditional signals. Variants with odds > 1:100 compared with the lead variant 
(corresponding to a p value 100 times larger than the most significant p value27) were 
selected as credible causal variants.
Results
Development of tissue/tumor-specific gene expression prediction models
We built genetically regulated gene expression predictor models using matched germline 
genotype and tumor gene expression data from TCGA by applying elastic net regularization 
as implemented in the PrediXcan software. Genes with models where the nested tenfold 
cross-validated correlation between predicted and actual levels of expression was >10% 
(predictive performance r2 > 0.01) and p value of the correlation test was <0.05 were 
retained in line with best practice quality control recommendations by the developers of 
PrediXcan.8 We constructed and evaluated predictor models that met these criteria for 4,457 
genes based on 681 TCGA breast tumor samples and for 2,705 genes based on 295 TCGA 
ovarian tumor samples. We obtained pre-computed genetically regulated gene expression 
predictor models that met the same criteria (predictive performance r2 > 0.01;correlation test 
p < 0.05) in matched germline genotype and normal tissue gene expression data from the 
GTEx Project. Specifically, the pre-computed data included 5,274 genes modeled based on 
211 GTEx breast tissue samples and 3,034 genes modeled based on 99 GTEx ovarian tissue 
samples. The variance of a gene’s expression explained by SNPs in its model was, on 
average, lower in tumors and higher in normal tissues (mean [standard deviation] for TCGA 
breast cancer: 0.04 [0.07];TCGA ovarian cancer: 0.05 [0.06)]; GTEx breast: 0.09 [0.09];and 
GTEx ovary: 0.15 [0.13]), likely reflecting the relatively smaller influence of germline 
genetic variation on tumor gene expression compared to its impact on normal tissue gene 
expression. Prediction performance as measured by the cross-validated correlation of the 
tissue model’s correlation to the gene’s measured transcriptome was, in general, 
substantially better for the normal tissue models than the tumor tissue models (Figure S1).
Imputation of gene expression into GWAS and pleiotropy-guided FDR control
We used the GTEx normal breast-tissue-derived prediction models to impute genetically 
regulated gene expression in a genome-wide association meta-analysis involving 122,977 
breast cancer cases and 105,974 controls using S-PrediXcan. We tested for association 
between imputed gene expression and breast cancer risk. We also used the same GTEx 
breast-tissue-based models to impute gene expression in a genome-wide association meta-
analysis of 22,406 ovarian cancer cases and 40,941 controls and test for association between 
imputed expression and ovarian cancer risk. For these two steps, we applied the conditional 
FDR method to the S-PrediXcan gene-level association p values to correct for testing 5,274 
genes in each analysis. This yielded two conditional FDR values: one for association with 
breast cancer risk given association with ovarian cancer risk and the other for association 
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with ovarian cancer risk given association with breast cancer risk. Finally, we took the larger 
of the two values for each gene as a conservative estimate of its conjunction FDR to identify 
candidate breast cancer susceptibility genes at conjunction FDR < 0.05. We refer to these 
genes as candidate breast cancer susceptibility genes because they were identified on the 
basis of gene expression predictor models derived from breast tissue. However, the 
conditional-conjunction FDR analysis effectively borrowed information from pleiotropic 
associations with inherited susceptibility to a second cancer type (in this case ovarian 
cancer) in addition to the primary cancer type (breast cancer), and these genes may be 
considered as risk genes for the second cancer as well. These steps were repeated for three 
other ordered combinations of datasets: TCGA breast tumor tissue-breast cancer GWAS-
ovarian cancer GWAS to identify candidate breast cancer susceptibility genes; GTEx normal 
ovarian tissue-ovarian cancer GWAS-breast cancer GWAS and TCGA ovarian tumor tissue-
ovarian cancer GWAS-breast cancer GWAS to identify candidate ovarian cancer 
susceptibility genes. We also replaced the overall breast cancer GWASs and all invasive 
ovarian cancer GWASs used in the four dataset combinations described above with ER-
negative breast cancer GWASs (21,468 cases/105,974 controls) and HGSOC GWASs 
(13,037 cases/22,406 controls), respectively. This helped identify additional candidate breast 
and ovarian cancer susceptibility genes driven by subtype-specific associations at 
conjunction FDR < 0.05.
For each gene, coverage was defined as the percentage of the number of variants included in 
its expression prediction model that were also captured in the genome-wide association 
meta-analysis. The coverage was ≥80% for at least 93% of the genes in each of the four 
matched germline genotype and normal or tumor gene expression datasets used to build the 
predictor models, indicating that for most genes, most of the corresponding model variants 
available were used. In each ordered analytic combination of datasets (e.g., GTEx normal 
breast tissue-breast cancer GWAS-ovarian cancer GWAS) we observed that, in general, for 
progressively smaller S-PrediXcan p values of the second cancer type, the true discovery 
rate for association with the primary cancer type approached 100% at progresssively larger 
S-PrediXcan p values for the primary cancer type (Figure 2; Figure S2). This was consistent 
with substantial shared gene-level associations for breast and ovarian cancer risk and these 
shared signals being tapped by the conditional-conjunction FDR method to power candidate 
susceptibility gene discovery.
Identification of candidate breast cancer and ovarian cancer susceptibility genes
We identified 14 candidate breast cancer susceptibility genes at the conjunction FDR < 0.05 
threshold (Table 1; Table S1). The 14 genes were distributed between 11 genomic regions >1 
Mb apart from each other (Table 1). These genes have not been reported as susceptibility 
genes in any prior TWAS of breast cancer risk and are >1 Mb away from published genome-
wide significant lead variants for breast cancer susceptibility.28 For ovarian cancer, we 
identified 8 candidate susceptibility genes at conjunction FDR < 0.05 (Table 2; Table S2). 
The 8 genes were located across 5 genomic regions >1 Mb apart from each other (Table 2). 
These genes have not been reported as candidate risk genes in any previously reported 
TWASs of ovarian cancer risk and are >1 Mb away from published genome-wide significant 
lead variants for ovarian cancer susceptibility.23
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Candidate breast cancer and ovarian cancer susceptibility genes at known GWAS loci
We identified 38 candidate breast cancer susceptibility genes that were located within 1 Mb 
of a published lead variant associated at genome-wide significance with breast cancer risk 
(Table S3).28 Four of the 38 genes have also been reported in previously published TWASs 
(Table S3).9,10 The 38 genes were spread across 12 genomic regions >1 Mb apart from each 
other. Overlaying fine-mapped candidate causal breast cancer risk variants on breast gene 
expression predictor model variants showed that for 21/38 (55%) genes, the prediction 
model variants included at least one fine-mapped candidate causal variant (Tables S3 and 
S4). This suggested that, for these genes, the GWAS association signal was driving the S-
PrediXcan signal. We also identified three additional genes that were >1 Mb away from 
known GWAS loci that have previously been reported as TWAS loci for breast cancer risk 
(Table S3).9,10
For ovarian cancer, we identified 17 candidate susceptibility genes that were located within 
1 Mb of a published lead variant associated at genome-wide significance with ovarian cancer 
risk (Table S5).23 Six of these genes have also been reported in a previously published 
TWAS for ovarian cancer (Table S5).11,12 The 17 genes span 5 different genomic regions >1 
Mb apart. Overlaying fine-mapped candidate causal ovarian cancer risk variants onto the 
ovarian gene expression predictor model variants showed that for 12/17 (71%) genes, the 
prediction model variants included at least one fine-mapped candidate causal variant (Tables 
S5 and S6), suggesting that for these genes the GWAS association signal underpinned the S-
PrediXcan signal.
Discussion
In this study, we used the conditional and conjunctional FDR as a tool to systematically 
improve the power of breast cancer and ovarian cancer candidate susceptibility gene 
discovery in a PrediXcan-based TWAS. While gene expression prediction models based on 
multiple tissue types have been the more common approach to improving TWAS power,11,29 
the conditional/conjunction FDR approach gains power through the incorporation of 
multiple related GWAS datasets into a TWAS analysis. We investigated the shared inherited 
genetic basis of these two cancer types by integrating normal and tumor-tissue-specific 
transcriptomic datasets with large-scale genome-wide association meta-analysis findings for 
susceptibility to breast cancer and ovarian cancer. We identified 11 genomic regions 
associated with breast cancer risk and five regions linked to ovarian cancer risk.
We identified 14 candidate breast cancer susceptibility genes (Table 1). Many of these genes 
have a strong biological rationale for involvement in breast carcinogenesis and are in or near 
genomic regions associated with other cancer types or potential cancer risk factors. For 
example, the ZNF276 (MIM: 608460) intronic variant rs12925026 is associated at genome-
wide significance with non-melanoma skin cancer.30 ZNF276 overlaps FANCA (MIM: 
607139) in a tail-to-tail manner.31 The genetically regulated predictor model for ZNF276 
expression was fit using gene expression measured in GTEx breast tissues, but neither this 
dataset nor any of the other datasets could capture a predictor model for FANCA expression. 
FANCA encodes one of eight subunits that together form the core Fanconi Anemia (FA) 
complex that repairs blockages in DNA replication due to cross-linking.32 Several members 
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of the FA family of proteins have been implicated in breast and ovarian cancer 
predisposition, including BRCA1 (FANCS), BRCA2 (FANCD1), BRIP1 (MIM: 605882) 
(FANCJ), PALB2 (MIM: 610355) (FANCN), RAD51C (MIM: 602774) (FANCO), and 
FANCM (MIM: 609644), and it is possible that FANCA may represent another or possibly 
the true target breast cancer susceptibility gene in this region, given this biological function 
and its overlap with ZNF276.32,33 ZNF276 in its own right has also been implicated as a 
candidate tumor suppressor gene in breast cancer,31 and consistent with this potential tumor 
suppressor function we observed that lower ZNF276 expression was associated with 
increased breast cancer risk.
Other candidate breast cancer susceptibility genes we identified include ESRP2 (MIM: 
612960), which encodes an epithelial cell-specific regulator of splicing of the breast cancer 
susceptibility gene FGFR2 (MIM: 176943)34,35 and SCGB1D2 (MIM: 615061), which 
encodes lipophilin B, which is known to be expressed in both breast and ovarian tumors.36 
Lipophilin B is tightly co-expressed with and forms a covalent complex with Mammaglobin 
A encoded by SCGB2A2, the gene next to SCGB1D2.36 Mammaglobin A may be used to 
detect disseminated or circulating tumor cells and is under investigation as a potential 
immunotherapeutic target in breast cancer.37 However, we were unable to develop gene 
expression prediction models for SCGB2A2 in breast normal or tumor tissues. BHLHA15 
(MIM: 608606) encodes an estrogen-regulated transcription factor that is required to 
maintain mammary gland differentiation in mice,38 and we found that decreased BHLHA15 
expression was associated with greater susceptibility to breast cancer. ETAA1 (MIM: 
613196) harbors lead variants associated at genome-wide significance with pancreatic 
cancer39 and the hormone-related traits of age at menopause40 and male-pattern baldness.41 
It encodes an activator of ATR kinase that accumulates at DNA damage sites and promotes 
replication fork progression and integrity.42 Breast cancer is closely linked to DNA damage 
repair defects, and, in the presence of DNA damage, further loss of ETAA1 has been shown 
to be synthetically lethal for the cell, suggesting that ETAA1 expression may be essential for 
tumorigenesis on a background of DNA damage.43 In keeping with this observation, we 
noted that elevated ETAA1 expression was associated with increased breast cancer risk. 
While our pleiotropy-guided transcriptome imputation study was ongoing, a genome-wide 
association meta-analysis for breast cancer risk that was performed in parallel identified lead 
variants rs79518236 (184 kb from BHLHA15) and rs9712235 (244 kb from ETAA1) at 
genome-wide significance only on addition of 10,407 breast cancer cases and 7,815 controls 
to the Michailidou et al.44 dataset used here. There were no known GWAS associations for 
breast cancer risk in these regions until the larger GWAS meta-analysis, and our concomitant 
identification of the same regions using gene expression imputation into a smaller GWAS 
underscores the power of leveraging expression data to bolster genetic discovery.
We identified 11 candidate ovarian cancer susceptibility genes (Table 2). As with breast 
cancer, there is strong support for a role of several genes in ovarian cancer pathogenesis, and 
many of these genes are in regions of the genome that harbor pleiotropic associations with 
other cancer types. Variants immediately upstream of CCNE1 (MIM: 123837) are associated 
at genome-wide significance with bladder cancer risk.45 CCNE1 amplification is believed to 
be an early event in the development of ovarian cancer46 and is a frequent somatic event in 
HGSOCs that do not carry homologous recombination DNA repair pathway defects.47 
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CCNE1 amplification is also associated with poor prognosis in triple-negative breast tumors,
48 and it is worth noting that we observed the stronger conjunction FDR association signal 
for CCNE1 in the pleiotropy-informed analysis that was based on the HGSOC and ER-
negative breast cancer susceptibility GWAS datasets (Table 2). However, we noted that 
increased CCNE1 expression was associated with decreased HGSOC (and ER-negative 
breast cancer) risk. This paradoxical direction of risk effect may be explained by the fact that 
CCNE1 amplification is less common and the loss of homologous recombination (HR) 
pathway function is far more common in ovarian cancer, and, in the absence of a functional 
HR pathway, CCNE1 is known to be essential for the developing tumor cell to survive.49 
This study suggests a role for CCNE1 in conferring ovarian cancer risk. Intronic variants in 
HEATR3 (MIM: 614951) are associated at genome-wide significance with glioma in 
European ancestry individuals50 and with squamous cell esophageal carcinoma in East 
Asian ancestry individuals.51 HEATR3 was also identified by a TWAS of glioma 
susceptibility.52 Intronic variants in THSD7A (MIM: 612249) are associated with epithelial 
ovarian cancer risk in East Asians,53 albeit not at genome-wide significance (lead variant 
rs10260419 p = 1 × 10−7). Gene expression prediction models derived from breast and 
ovarian tissues both implicated the 15q15.3 region as a breast and ovarian cancer 
susceptibility region on imputation with these models into the breast and ovarian cancer 
GWAS data. Our analysis suggested several genes in this region (Tables 1 and 2), with the 
pseudogene STRCP1 as the only common gene across breast and ovarian tissues. STRCP1 
overlaps the protein coding gene STRC (MIM: 606440), also identified in the breast-tissue-
based analysis (Table 1), and variants in STRC have previously been associated with lung 
cancer risk (lung cancer lead variant rs35028925 p = 2 × 10−6).54
In this analysis, we chose to label the identified genes as candidate breast cancer 
susceptibility genes if they were identified on integrating the GTEx or TCGA breast 
expression prediction models with the breast cancer GWASs and incorporating pleiotropic 
information from the ovarian cancer GWASs and vice versa for candidate ovarian cancer 
susceptibility genes. However, application of the conjunction FDR over and above the 
conditional FDR in principle identified genes associated with both cancer types by tapping 
into GWAS data from both cancers. Therefore, in a sense, all these genes may well be 
regarded as candidate breast and ovarian cancer susceptibility genes. Moreover, in our 
pleiotropy-guided study design, the ovarian cancer dataset, in a sense, served as a replication 
dataset for the breast cancer findings and vice versa, which was particularly important given 
the lack of adequately powered and truly independent breast and ovarian cancer datasets 
outside of the datasets used in this study.55
We identified 38 candidate breast cancer susceptibility genes and 17 candidate ovarian 
cancer susceptibility genes in regions previously implicated by GWASs for breast cancer and 
ovarian cancer, respectively (Tables S3 and S5). The identification of a large number of 
genes in these regions is unsurprising, given that GWAS associations are the key determinant 
of the S-PrediXcan signal. However, we were able to take advantage of fine-scale mapping 
data generated by the Breast and Ovarian Cancer Association Consortia to separately 
pinpoint those genes where a fine-mapped candidate causal GWAS risk variant was 
incorporated in the PrediXcan model, suggesting that it drives the gene-based association. 
Overall, we found this to be the case for 60% of the candidate susceptibility genes identified 
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by PrediXcan in the breast and ovarian cancer susceptibility regions identified by GWASs. 
Comprehensive functional follow-up of the 19p13.11 breast and ovarian cancer GWAS 
region suggests that ABHD8 and ANKLE1 are the most likely targets in this region.5 While 
there was no overlap between S-PrediXcan model variants for ABHD8 and ANKLE1 and 
fine-mapped risk variants in this region, S-PrediXcan did detect both genes as candidate 
causal susceptibility genes, with ANKLE1 being the only gene that made the cut in both 
breast and ovarian tissues, suggesting that S-PrediXcan applied to pleiotropic gene-dense 
regions such as 19p13.11 does help short-list the key targets even in the absence of overlap 
with fine-mapped variants. A total of 21/38 breast and 13/17 ovarian cancer candidate 
susceptibility genes in the published GWAS regions were clustered at 17q21.31, reflecting 
the unique long-distance linkage disequilibrium structure of this region.56 This phenomenon 
has also led to clustering of associations at 17q21.31 in previous TWASs of breast or ovarian 
cancer risk.9,11
Gene expression prediction models in this study were built using genomic data from women 
with genetically inferred European ancestry. The predictive performance of these models in 
a non-European ancestry cohort was not evaluated. Thus, a key limitation of this study is the 
potential lack of generalizability of these models to non-European ancestry cohorts. Recent 
analyses suggest that default TWAS models trained in large datasets such as GTEx suffer 
from a significant reduction in prediction accuracy, particularly in individuals of African 
ancestry, when compared to those of European ancestry.57 There is an urgent and compelling 
need for trans-ancestry datasets that drive TWAS in diverse ancestral cohorts.
In conclusion, the powerful combination of pleiotropic breast and ovarian cancer GWAS 
datasets with transcriptome imputation from normal and tumor breast and ovarian tissues 
identified a total of 16 genomic loci (22 genes) associated with breast and ovarian cancer 
risks. Fine-mapping in larger GWAS datasets and deeper laboratory-based functional follow-
up studies of these loci and candidate genes have the potential to provide fresh insights into 
the common biological underpinnings of breast and ovarian cancer.
Data and code availability
All datasets analyzed in this study are publicly available: Genome-wide summary genetic 
association statistics from BCAC are available at: http://bcac.ccge.medschl.cam.ac.uk/
bcacdata/oncoarray/oncoarray-and-combined-summary-result/gwas-summary-results-breast-
cancer-risk-2017/. Genome-wide summary genetic association statistics from OCAC are 
available at: https://www.ebi.ac.uk/gwas/downloads/summary-statistics (please search the 
GWAS catalog at the link above using the study accession numbers GCST004415 for the 
overall ovarian cancer and GCST004480 for the HGSOC datasets). PrediXcan prediction 
models trained on the GTEx version 7 data (including breast and ovarian tissues) are 
available here: https://zenodo.org/record/3572799. PrediXcan prediction models trained on 
the TCGA data (breast and ovarian tumors) are available here: https://zenodo.org/record/
3818295. Code, including a tutorial, for running S-PrediXcan is available here: https://
github.com/hakyimlab/MetaXcan. The data used for the analyses described in this 
manuscript can be obtained from dbGaP via accession number phs000424.
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Figure 1. Overview of datasets and analyses in this study
Flowchart providing an overview of the datasets used and the various steps in the analysis. 
GTEx, Genotype-Tissue Expression project; TCGA, The Cancer Genome Atlas; GWAS, 
genome-wide association study; FDR, false discovery rate.
Kar et al. Page 18













Figure 2. True discovery rate of S-PrediXcan associations for each cancer stratified by 
associations with the other cancer
True discovery rate against the negative logarithm (base 10) of the p value for each cancer 
for subsets of genes based on strength of association with the other cancer. The y axis of 
each plot is the true discovery rate, which is defined as 1 – conditional FDR (cFDR). For a 
given ordered analytic combination of datasets (e.g., GTEx normal breast tissue as 
transcriptome reference panel-breast cancer GWAS-ovarian cancer GWAS, plotted in the 
upper left corner) we observed that, in general, for progressively smaller S-PrediXcan p 
values of the second cancer type (indicated by the key “Threshold p” next to each plot), the 
true discovery rate (y axis) for association with the primary cancer type approached 100% at 
progressively larger S-PrediXcan p values for the primary cancer type (x axis; negative 
logarithm [base 10] of the p values). Only p values > 10−6 are plotted on the x axis. BC, 
overall breast cancer risk; OC, all invasive ovarian cancer risk.
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